PharmaTher Holdings Ltd (PHRM) AI Stock Analysis

• Market Cap: C$11.83M
• Dividend Yield: N/A
• Average Volume (3M): 210.04K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: N/A
• EPS Growth: 27.35%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 91,019,066
• 10 Day Avg. Volume: 126,338
• 30 Day Avg. Volume: 210,037
• PEG Ratio: 0.20
• Price to Book (P/B): 16.46
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.11
• Revenue Forecast (FY): C$38.92M

• Rating: 44 Neutral
• Price Target: ―

PharmaTher Holdings Ltd. faces substantial financial hurdles, with no revenue and persistent losses weighing heavily on its stock score. However, recent positive corporate developments regarding FDA approval for ketamine could provide a significant future boost. Technical indicators are currently neutral, and valuation metrics reflect typical challenges for biotech firms in early stages. The potential regulatory approval is a key factor for future growth, but immediate financial struggles limit the current score.

PharmaTher Holdings Ltd Business Overview & Revenue Model

Company Description

PharmaTher Holdings Ltd (PHRM) is a clinical-stage biotech company focused on the research and development of psychedelic pharmaceuticals. The company's primary aim is to advance the clinical development of novel uses for psychedelic compounds, such as ketamine and psilocybin, in the treatment of mental health disorders, neurological diseases, and pain management. PharmaTher leverages its expertise in drug development and delivery systems to create innovative therapeutic solutions that address unmet medical needs.

How the Company Makes Money

PharmaTher Holdings Ltd generates revenue primarily through the development and commercialization of its proprietary psychedelic-based therapies. The company's revenue model includes licensing agreements, partnerships, and collaborative research and development efforts with other pharmaceutical companies. These agreements often involve upfront payments, milestone payments, and royalties on sales of successful therapies. Additionally, PharmaTher may receive funding from grants and government programs that support research in psychedelic medicine. The company's focus on strategic collaborations and intellectual property development plays a critical role in its ability to generate revenue and sustain growth in the competitive biotech landscape.

PharmaTher Holdings Ltd Financial Statement Overview

Summary

PharmaTher Holdings Ltd faces significant financial challenges, with no revenue generation and consistent operational losses. Despite a strong equity position due to zero debt, declining assets and equity raise concerns about financial health. Negative cash flows highlight the company's dependence on external financing, emphasizing the need for strategic changes to improve revenue generation and operational efficiency.

Income Statement

The company has consistently reported zero revenue over recent periods, indicating a lack of income generation from its operations. Net income remains negative, with significant losses reported, which is a concern for financial sustainability. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies and high costs relative to non-existent revenues. The company faces challenges in achieving profitability.

Balance Sheet

The company maintains a strong equity position with zero debt, resulting in a favorable debt-to-equity ratio. However, the declining stockholders' equity and total assets over time reflect potential asset erosion and reduced investor support. The absence of liabilities provides financial stability, yet the overall decrease in assets and equity remains a concern.

Cash Flow

Operating cash flow is consistently negative, indicating cash outflows from core operations. Free cash flow also remains negative, suggesting the company struggles to generate cash to fund operations or growth. The reliance on financing activities for cash inflow suggests potential difficulties in sustaining operations without external funding.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-711.00	-1.42K	-1.78K	-355.00
EBITDA	-1.55M	-1.52M	-3.04M	-3.96M	-3.96M	-2.43M
Net Income	-1.53M	-1.53M	-3.12M	-6.42M	-4.01M	2.66M
Balance Sheet
Total Assets	1.34M	1.34M	2.59M	6.31M	12.16M	5.94M
Cash, Cash Equivalents and Short-Term Investments	1.12M	1.12M	2.30M	6.25M	12.12M	5.88M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	366.33K	366.33K	252.90K	892.48K	330.32K	361.06K
Stockholders Equity	973.54K	973.54K	2.34M	5.42M	11.83M	5.58M
Cash Flow
Free Cash Flow	-1.21M	-1.21M	-3.52M	-3.24M	-3.51M	917.92K
Operating Cash Flow	-1.21M	-1.21M	-3.52M	-3.24M	-3.51M	922.19K
Investing Cash Flow	0.00	0.00	-300.00K	0.00	0.00	214.77K
Financing Cash Flow	0.00	0.00	35.00K	0.00	9.89M	1.25M

PharmaTher Holdings Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.13
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PHRM, the sentiment is Negative. The current price of 0.13 is above the 20-day moving average (MA) of 0.12, below the 50-day MA of 0.20, and below the 200-day MA of 0.27, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 43.73 is Neutral, neither overbought nor oversold. The STOCH value of 60.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PHRM.

PharmaTher Holdings Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHRM	44 Neutral	C$11.83M	―	-112.32%	―	―	27.35%
BCT	43 Neutral	C$26.64M	-0.13	-342.38%	―	―	-81.77%
HEM	41 Neutral	C$17.48M	-3.24	―	―	―	-28.51%
DOSE	36 Underperform	C$21.37M	-4.62	―	―	95.76%	22.56%

PharmaTher Holdings Ltd Corporate Events

PharmaTher Receives FDA Approval Goal Date for Ketamine

PharmaTher Holdings Ltd. announced that it has received an Amendment Acknowledgement Letter from the U.S. FDA for its New Drug Application for Ketamine, with an approval goal date set for June 4, 2025. This development positions PharmaTher to potentially become a leading supplier of Ketamine in the U.S., addressing the ongoing shortage and filling the demand gap. The company has addressed minor deficiencies noted by the FDA and aims to remove Ketamine from the FDA’s drug shortage list, which would restrict compound pharmacies from supplying it, thereby strengthening PharmaTher’s market position.

PharmaTher Resubmits FDA Application for Ketamine, Aiming for Q2-2025 Approval

PharmaTher Holdings Ltd. has resubmitted its application to the FDA for the approval of Ketamine, addressing minor deficiencies previously noted by the agency. The company anticipates FDA approval in the second quarter of 2025, which could significantly impact the Ketamine shortage in the U.S. and enhance its use in treating various medical conditions. This move positions PharmaTher as a key player in addressing the Ketamine shortage and unlocking its potential for broader medical applications.

PharmaTher Advances Towards FDA Approval for Ketamine with Resubmission Plan

PharmaTher Holdings Ltd. announced that it is on track to resubmit information to the FDA by the end of February 2025, following a complete response letter that identified minor deficiencies. The company anticipates that this minor amendment will lead to a new FDA approval date in the second quarter of 2025 for ketamine, which is essential for anesthesia and pain relief, and is also used for mental health and neurological disorders. The successful approval could significantly strengthen PharmaTher’s market position as a key innovator in ketamine-based treatments, potentially impacting millions of patients worldwide.